Pharmaceutical giant GlaxoSmithKline spent over £320m bribing Chinese doctors to prescribe its products, according to the country's police.
The firm behaved like a "criminal godfather" by channelling payments through 700 intermediaries, and was also involved in "sexual bribery" in exchange for business, a six-month investigation alleged. "It is like a criminal organisation, there is always a boss. In this game, GSK is the godfather," Gao Feng, head of the Chinese anti-fraud unit, is reported to have said. Other foreign firms could also be implicated, he added. The allegations, which date back to 2007, were branded "serious" by the drug maker. Some of the intermediaries listed themselves as travel agents, and alleged...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes